Infliximab treatment for severe granulomatous disease in common variable immunodeficiency: a case report and review of the literature

To our knowledge, this is the first report of severe visceral granulomatous CVID successfully treated with infliximab. Infliximab may be an effective therapy for granulomas in CVID. Further studies of infliximab and other tumor necrosis factor α antagonist therapies in granulomatous CVID are warranted.